Navigation Links
KineMed to Present at the 4th Annual BIO Investor Forum
Date:10/8/2007

EMERYVILLE, Calif., Oct. 8 /PRNewswire/ -- KineMed Inc., a privately held pathway-based drug discovery and development company announced today that David M. Fineman, CEO and President of KineMed, will present an overview of the company and its drug development programs at the 4th Annual BIO Investor Forum in San Francisco on Thursday, October 11 at 2:00 p.m. PDT in the Pacific Heights room of the Palace Hotel. Mr. Fineman will provide an update on the company's lead discovery and development programs centered on cardio-metabolic disorders including atherosclerosis, and diabetes and dyslipidemia. Mr. Fineman will also discuss KineMed's internal drug development program in ALS and provide an overview on the company's partnering and collaboration efforts, including KineMed's clinical development collaborations with Merck & Co., Inc. and Merck KGaA to advance drugs that increase reverse cholesterol transport.

About KineMed

KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag(TM) and KineMarker(TM)) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, and diseases of inflammation and neurodegeneration. KineMed is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease. The Company has multiple development programs with more than a dozen major pharmaceutical companies, including Bayer, Merck & Co., Inc., Merck KGaA, Organon and Roche.

For further information about KineMed, please visit: http://www.kinemed.com/

Contact:

Brent Vaughan, Chief Business Officer of KineMed Inc., +1-510-655-6525,

ext. 110

Media:

Justin Jackson of Burns McClellan, jjackson@burnsmc.com

Investors:

John Cummings, jcummings@burnsmc.com, both of Burns McClellan,

+1-212-213-0006, both for KineMed Inc.


'/>"/>
SOURCE KineMed, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017 Dr. ... international life sciences corporation Anpac Bio-Medical Science ... a new, international record, processing and reporting over ... "Cancer Differentiation Analysis" (CDA) liquid biopsy tests. ... Nobel Prize Laureate Summit publications, Anpac Bio,s CDA ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... brand-new, fully-certified hygienic SWB805 MultiMountTM weigh modules. These weigh modules are designed ... by National Sanitation Foundation (NSF). , As fully integrated weighing solutions, SWB805 ...
(Date:3/27/2017)... Branford, Connecticut (PRWEB) , ... March 27, 2017 ... ... company dedicated to accelerating the fight against cancer, autoimmune disease and more through ... to the single-cell metabolomics and proteomics analysis platform developed in the laboratory ...
(Date:3/27/2017)... 2017  Perthera,s Chief Bioinformatics Officer and research faculty ... , Ph.D., will be speaking at the American Medical ... March 27, 2017, she will be speaking on the ... Research and Care" (from 10:30 a.m. – 12:00 p.m. ... be a participant in the "Making Precision Oncology Data ...
Breaking Biology Technology:
(Date:2/27/2017)... WASHINGTON , Feb. 27, 2017   Strategic ... fund, today announced it has led a $3.5 million investment ... collaboration platform. Strategic Cyber Ventures is DC based and ... and Hank Thomas . Ron Gula , ... Tech Ventures, also participated in this series A round ...
(Date:2/22/2017)... With the biometrics market to exceed ... technologies that innovative and agile startups must incorporate ... the changing competitive landscape: multifactor authentication (MFA), point-of-sale ... "Companies can no longer afford to cut ... Dimitrios Pavlakis , Industry Analyst at ABI Research. ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
Breaking Biology News(10 mins):